Tempest Therapeutics Inc (TPST)

$1.83 -0.26 (-12.44%)
Market Cap 26.39M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 270,500
Avg Vol 224,724
Day's Range N/A - N/A
Shares Out 14.34M
Stochastic %K 76%
Beta -1.75
Analysts Strong Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Michl2000
Michl2000 May. 15 at 7:40 PM
$TPST as always. One step ahead and two steps back.
0 · Reply
Michl2000
Michl2000 May. 15 at 6:38 PM
$TPST 💩💩💩
0 · Reply
Xamayca
Xamayca May. 15 at 5:07 PM
$TPST certainly doesnt t seem like they are sweating the cash on hand hmmm!
0 · Reply
frankPF
frankPF May. 15 at 4:02 PM
$TPST konnte nicht wiederstehen,1.88 ist ein guter Preis zum nachkaufen.Gesammtmarkt schwach,Tempest Stabil bei 1.88....was will man mehr ....warten auf mehr Volumen für neue Anläufe
2 · Reply
lousjamsession
lousjamsession May. 15 at 2:25 PM
$TPST
0 · Reply
claybridge
claybridge May. 15 at 2:09 PM
$TPST ahhh, memories...
2 · Reply
josegodoy
josegodoy May. 15 at 1:59 PM
$TPST still good
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy May. 15 at 1:34 PM
$TPST perfect day give us below $1 please and thank you
0 · Reply
TwongStocks
TwongStocks May. 15 at 1:31 PM
$TPST Sabby filed their 13F to report positions held on March 31. https://www.sec.gov/Archives/edgar/data/1535610/000110465926061764/xslForm13F_X02/primary_doc.xml The info table of all their holdings can be viewed here---> https://www.sec.gov/Archives/edgar/data/1535610/000110465926061764/xslForm13F_X02/infotable.xml Sabby reports ownership of 17,856 TPST shares with a market value of $29,284 as of March 31. Closing price on March 31 was $1.64. $1.64 x 17,856 = $29,283.84 In their previous 13F, they reported ownership of 178,592 shares as of Dec 31 👇.
2 · Reply
fantastex
fantastex May. 15 at 11:43 AM
$TPST big fellas unloaded the shorts AH and they are bullish on the next data for exit liquidità....see this coming. Expecting a 40% pump here
0 · Reply
Latest News on TPST
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:15 PM EDT - 1 day ago

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 9 days ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Apr 29, 2026, 8:00 AM EDT - 16 days ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics provides update on development of TPST-2003

2026-04-22T12:30:21.000Z - 23 days ago

Tempest Therapeutics provides update on development of TPST-2003

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 22, 2026, 8:00 AM EDT - 23 days ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 14, 2026, 8:00 AM EDT - 4 weeks ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-04-02T10:11:28.000Z - 6 weeks ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

2026-03-30T22:05:33.000Z - 6 weeks ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 9:00 AM EDT - 6 weeks ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Mar 23, 2026, 8:00 AM EDT - 7 weeks ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

2026-03-11T12:06:24.000Z - 2 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

2026-02-25T13:24:11.000Z - 2 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 25, 2026, 7:59 AM EST - 2 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 3 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 3 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2026-01-22T11:12:02.000Z - 4 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 4 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

2025-12-09T21:55:14.000Z - 5 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 6 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

2025-11-25T13:05:18.000Z - 6 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 6 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

2025-11-19T14:11:00.000Z - 6 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 6 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 6 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 6 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

2025-08-11T20:55:19.000Z - 9 months ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 9 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

2025-06-30T14:37:56.000Z - 11 months ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest prices 739,000 shares at $6.25 in registered direct offering

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

2025-05-13T20:35:15.000Z - 1 year ago

Tempest Therapeutics reports Q1 EPS ($3.16), consensus ($3.29)

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Therapeutics announces FDA granted ODD to TPST-1495

2025-04-21T12:08:31.000Z - 1 year ago

Tempest Therapeutics announces FDA granted ODD to TPST-1495

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 9:10 AM EST - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 3:00 PM EST - 2 years ago

Tempest Therapeutics Transcript: Piper Sandler 35th Annual Healthcare Conference

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Michl2000
Michl2000 May. 15 at 7:40 PM
$TPST as always. One step ahead and two steps back.
0 · Reply
Michl2000
Michl2000 May. 15 at 6:38 PM
$TPST 💩💩💩
0 · Reply
Xamayca
Xamayca May. 15 at 5:07 PM
$TPST certainly doesnt t seem like they are sweating the cash on hand hmmm!
0 · Reply
frankPF
frankPF May. 15 at 4:02 PM
$TPST konnte nicht wiederstehen,1.88 ist ein guter Preis zum nachkaufen.Gesammtmarkt schwach,Tempest Stabil bei 1.88....was will man mehr ....warten auf mehr Volumen für neue Anläufe
2 · Reply
lousjamsession
lousjamsession May. 15 at 2:25 PM
$TPST
0 · Reply
claybridge
claybridge May. 15 at 2:09 PM
$TPST ahhh, memories...
2 · Reply
josegodoy
josegodoy May. 15 at 1:59 PM
$TPST still good
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy May. 15 at 1:34 PM
$TPST perfect day give us below $1 please and thank you
0 · Reply
TwongStocks
TwongStocks May. 15 at 1:31 PM
$TPST Sabby filed their 13F to report positions held on March 31. https://www.sec.gov/Archives/edgar/data/1535610/000110465926061764/xslForm13F_X02/primary_doc.xml The info table of all their holdings can be viewed here---> https://www.sec.gov/Archives/edgar/data/1535610/000110465926061764/xslForm13F_X02/infotable.xml Sabby reports ownership of 17,856 TPST shares with a market value of $29,284 as of March 31. Closing price on March 31 was $1.64. $1.64 x 17,856 = $29,283.84 In their previous 13F, they reported ownership of 178,592 shares as of Dec 31 👇.
2 · Reply
fantastex
fantastex May. 15 at 11:43 AM
$TPST big fellas unloaded the shorts AH and they are bullish on the next data for exit liquidità....see this coming. Expecting a 40% pump here
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy May. 15 at 11:32 AM
$TPST Not worried. Not selling. Don't listen to all the negative Nelly's. I cashed in BIG on SLS and counting and can wait as long as it takes 👊
2 · Reply
josegodoy
josegodoy May. 15 at 10:24 AM
$TPST let’s see what happens
0 · Reply
josegodoy
josegodoy May. 15 at 10:21 AM
$TPST a position will act and react in accordance to who is holding the shares, so…who is holding the (bulk of the) shares? - also, while dilution is still dilution….the great dilutive threat is ATMs….Are the buyers buying the dilutive shares well informed?
0 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 15 at 10:12 AM
$TPST yep heavy dilution on the way
0 · Reply
HappyGentelmen
HappyGentelmen May. 15 at 8:48 AM
$TPST another 4000% Run is coming.? I hope so!
0 · Reply
Xamayca
Xamayca May. 15 at 8:16 AM
$TPST We did not get to price discovery under Brady because he was a failure who desperately punted in a bid to stave off reality, he, did however set the stage for price discovery by putting the pieces in place for a sale or licensing deal in Asian markets (legacy assets) I’m not so sure Angel and his backers are prepared to wait out a good deal for those assets in fact I hope not, but I have to believe they have enough leverage and will extend the Ron way enough to where we get at least a couple hundred million out of the deal to fund their CAR-T ambitions
0 · Reply
Xamayca
Xamayca May. 15 at 1:37 AM
$TPST No point in abandoning this . The one time charge on the deal closing is behind us cash on hand was 1.7 mil dilutive funding of approx $400K per month which is being held pay the CEO is not really dilutive as it won’t hit the open market . The cash situation isn’t great but it’s not so desperate as others are implying. And it also increases the likelihood of a near term deal for legacy assets!
0 · Reply
josegodoy
josegodoy May. 14 at 10:56 PM
$TPST Let’s see what happens tomorrow - I’m looking for some price movements to confirm bullishness (up & down) YES, there WILL in all likelihood be multiple offerings (going forward)
1 · Reply
claybridge
claybridge May. 14 at 10:27 PM
$TPST those warrants were prefunded, meaning the company already got that $ in March. Expect an offering in days.
0 · Reply
fantastex
fantastex May. 14 at 10:16 PM
$TPST we need that 2.16 to be hit for the warrants fellas to get some money in the bank. Let's pump it up
0 · Reply
MoneyorBagHolder
MoneyorBagHolder May. 14 at 9:34 PM
$TPST I am out with loss.
2 · Reply
TwongStocks
TwongStocks May. 14 at 9:11 PM
$TPST 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526224289/tpst-20260331.htm • 14,806,997 shares outstanding as of May 8 • As of March 31, 2026, $13.8 million of availability remained under the Factor Funding Commitment. • All 2026 Pre-Funded Warrants from the March 2026 offering were subsequently exercised in April 2026.
0 · Reply